Stiripentol for the treatment of pharmacoresistant epilepsy with drug eruptions

Stiripentol for the treatment of pharmacoresistant epilepsy with drug eruptions - STP for pharmacoresistant epilepsy with drug eruptions

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034986

Enrollment

Registered

2018-11-25

Start date

2018-11-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pharmacoresistant epilepsy with drug eruptions

Interventions

Stiripentol: the initial dose was low (500 mg/d) and was then increased stepwise (500 mg/wk) until reaching a maintenance dose Anti-epileptic drugs other than Stiripentol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pharmacoresistant epilepsy with drug eruptions Patients were included in the study after giving informed consent.

Exclusion criteria

Exclusion criteria: Others than those above

Design outcomes

Primary

Measure	Time frame
The efficacy of Stiripentol for both epileptic seizure and drug eruption	—

Countries

Japan

Contacts

Public ContactYuto Uchida

Nagoya City University Neurology

uchidayuto0720@yahoo.co.jp0528538094

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026